Compare Koninklijke Philips NV (PHG) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Koninklijke Philips NV vs Twist Bioscience Corp — how do they compare? Koninklijke Philips NV trades at $26.3 (market cap $25.89B), while Twist Bioscience Corp trades at $93.82 (market cap $5.97B). The key difference: Koninklijke Philips NV is far larger — about 4.3× Twist Bioscience Corp's market cap, and Koninklijke Philips NV pays a 3.81% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| PHG | TWST | |
|---|---|---|
Market Cap | $25.89B | $5.97B |
Sector | Health | Health |
52-Week High | $32.91 | $102.88 |
52-Week Low | $25.02 | $24.16 |
Enterprise Value | $32.18B | $5.89B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PHG trades at $26.58, down 1.37% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported net income of $895 million in 2025, a significant recovery from prior losses, with a net margin of 5.5%. Recent FDA clearances for medical devices and AI integrations highlight ongoing innovation. Cash flow from operations remains positive at $1.17 billion for 2025, though net cash flow declined to $403 million.
The outlook is mixed: analyst consensus is neutral with 59% hold ratings, reflecting caution despite recent profitability improvements. Key risks include high debt levels, with debt-to-asset ratio at 25.44% in 2025, and competitive pressures in health technology. Upside potential hinges on execution of AI-driven growth initiatives and margin expansion, as noted in Seeking Alpha analysis on 2026-05-20.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
